Efficacy of Endoscopic Sutured Gastroplasty on Diabetes Mellitus Type 2—A Systematic Review

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Endocrinology, Diabetes and Metabolism Pub Date : 2025-05-30 DOI:10.1002/edm2.70057

Fenna M. M. Beeren, Mitchell J. R. Harker, Arianne C. van Bon, Marcel J. M. Groenen, Peter D. Siersema

{"title":"Efficacy of Endoscopic Sutured Gastroplasty on Diabetes Mellitus Type 2—A Systematic Review","authors":"Fenna M. M. Beeren, Mitchell J. R. Harker, Arianne C. van Bon, Marcel J. M. Groenen, Peter D. Siersema","doi":"10.1002/edm2.70057","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Endoscopic sutured gastroplasty (ESG) is one of the currently available endoscopic techniques that mimics bariatric surgery. Although the efficacy of ESG on weight loss has repeatedly been demonstrated, its effect on diabetes mellitus type 2 (T2DM) related outcomes is not yet fully clear.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a systematic review summarising the efficacy of ESG on T2DM. Therefore, PubMed, Embase and Cochrane library were searched for studies evaluating the effect of ESG on T2DM. Both prospective and retrospective studies, published in the English language, were included. Two reviewers independently screened all studies. The primary objectives were T2DM remission rate, decrease in glucose-lowering medication and decrease in HbA1c.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 16 studies including 760 patients with (pre)diabetes were included. Overall, T2DM-related outcomes after ESG improved in 303 of 599 patients (50.6%) (including tapering dose of insulin and/or improvement of HbA1c/fasting glucose). Remission rates of T2DM were reported in 6/11 studies and seen in 89 of 155 (57.0%) patients after 6–36 months.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This systematic review on the efficacy of ESG on T2DM suggests that ESG is able to improve diabetes-related outcomes in approximately half of treated patients, with T2DM remission rates in more than half of them.</p>\n </section>\n </div>","PeriodicalId":36522,"journal":{"name":"Endocrinology, Diabetes and Metabolism","volume":"8 4","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/edm2.70057","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinology, Diabetes and Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/edm2.70057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Endoscopic sutured gastroplasty (ESG) is one of the currently available endoscopic techniques that mimics bariatric surgery. Although the efficacy of ESG on weight loss has repeatedly been demonstrated, its effect on diabetes mellitus type 2 (T2DM) related outcomes is not yet fully clear.

Methods

We conducted a systematic review summarising the efficacy of ESG on T2DM. Therefore, PubMed, Embase and Cochrane library were searched for studies evaluating the effect of ESG on T2DM. Both prospective and retrospective studies, published in the English language, were included. Two reviewers independently screened all studies. The primary objectives were T2DM remission rate, decrease in glucose-lowering medication and decrease in HbA1c.

Results

A total of 16 studies including 760 patients with (pre)diabetes were included. Overall, T2DM-related outcomes after ESG improved in 303 of 599 patients (50.6%) (including tapering dose of insulin and/or improvement of HbA1c/fasting glucose). Remission rates of T2DM were reported in 6/11 studies and seen in 89 of 155 (57.0%) patients after 6–36 months.

Conclusion

This systematic review on the efficacy of ESG on T2DM suggests that ESG is able to improve diabetes-related outcomes in approximately half of treated patients, with T2DM remission rates in more than half of them.

Abstract Image

查看原文本刊更多论文

内镜下胃缝合成形术治疗2-A型糖尿病的疗效综述

内镜下缝合胃成形术（ESG）是目前可用的内镜技术之一，模仿减肥手术。虽然ESG对减肥的疗效已被反复证实，但其对2型糖尿病（T2DM）相关结局的影响尚未完全清楚。方法我们对ESG治疗T2DM的疗效进行了系统综述。因此，我们检索了PubMed、Embase和Cochrane文库，以评估ESG对T2DM的影响。以英语发表的前瞻性和回顾性研究均包括在内。两名审稿人独立筛选了所有研究。主要目标是T2DM缓解率，降糖药物减少和HbA1c降低。结果共纳入16项研究，760例糖尿病（前期）患者。总体而言，599例患者中有303例（50.6%）ESG后t2dm相关结果得到改善（包括胰岛素剂量逐渐减少和/或HbA1c/空腹血糖改善）。6/11项研究报告了T2DM的缓解率，155例患者中有89例（57.0%）在6-36个月后出现缓解率。结论：关于ESG治疗T2DM疗效的系统综述表明，ESG能够改善大约一半的治疗患者的糖尿病相关结局，其中超过一半的患者的T2DM缓解率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊